Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Matrix metalloproteinase-25 (MMP-25) is a member of the membrane-type MMP (MT-MMP) subfamily, attached to the plasma membrane via a glycosylphosphatidyl inositol anchor. Unlike most MMPs that are secreted as inactive proproteins requiring cleavage for activation, MMP-25 has a specific membrane attachment mechanism. In response to bacterial infection or inflammation, MMP-25 is thought to inactivate alpha-1 proteinase inhibitor, which is a major tissue protectant against proteolytic enzymes released by activated neutrophils. This inactivation facilitates the transendothelial migration of neutrophils to inflammatory sites. Additionally, MMP-25 may play a significant role in tumor invasion and metastasis through the activation of MMP2. The gene was previously referred to as MMP20 but has been renamed MMP25. MMP-25 is also known as MT6-MMP or Leukolysin and is capable of degrading various extracellular matrix components, including proMMP-2, fibronectin, and gelatin.
Cleaves extracellular matrix proteins Activates MMP-2 (proMMP-2)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Matrix metallopeptidase 25 (MMP-25).